The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Predictors of infection in patients with myelofibrosis receiving ruxolitinib
Francesca Palandri, MD, PhD, University of Bologna, Bologna, Italy, discusses predictors of infection in patients with myelofibrosis receiving ruxolitinib. She highlights the impact of transfusion dependence, iron overload, and elevated neutrophil-to-lymphocyte ratio, emphasizing the importance of monitoring anemia and inflammatory status to reduce infection risk.This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
